ONO-7018 and the MALT1 paracaspase: a first-in-class inhibitor stopped at nine patients

What was tried

Ono Pharmaceutical ran a Phase 1, open-label, sequential dose-escalation study of ONO-7018, an orally administered small-molecule inhibitor of the MALT1 paracaspase, in adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia (NCT05515406). The primary objectives were the maximum tolerated dose and the incidence of treatment-emergent adverse events, with pharmacokinetics, pharmacodynamic biomarkers, and preliminary efficacy as secondary readouts. The compound, also described in preclinical work as CTX-177, was positioned as first-in-class for this target. The trial enrolled 9 participants (actual) before Ono terminated it, recording the reason as a strategic decision to discontinue development (ClinicalTrials.gov NCT05515406). Primary completion was logged on 13 August 2025, and no results were posted.

The biological hypothesis

MALT1 sits at the center of antigen-receptor signaling to NF-kB. It acts as both a scaffold and a protease, and its catalytic activity cleaves negative regulators of NF-kB such as the deubiquitinase CYLD (Nature Immunology 2008). In the activated B-cell subtype of diffuse large B-cell lymphoma and in mantle cell lymphoma, chronic B-cell receptor signaling drives constitutive MALT1 activity, which sustains the survival program these tumors depend on (Clinical Cancer Research 2013). Blocking the protease was expected to collapse that survival signal. Preclinical packages reported activity in activated B-cell lymphoma and mantle cell models, plus synergy with Bruton tyrosine kinase inhibitors and a route around acquired BTK-inhibitor resistance (Cancer Treatment Reviews 2023). The disruption of the BCL10-MALT1 interaction has been pursued as a parallel strategy (Journal of Clinical Investigation 2025). The thesis was mechanistically coherent and supported by a decade of pathway biology.

What actually happened

The study stopped at 9 patients with no posted efficacy or safety dataset. The recorded reason was strategic, not a futility boundary or a safety hold (ClinicalTrials.gov NCT05515406). A dose-escalation design that closes after single-digit enrollment rarely reaches the MTD it was built to define, which means the program ended before it generated the human pharmacodynamic evidence that would confirm or refute target engagement at tolerated doses. Open Targets records a target-disease association score of 0.0102 for MALT1 against non-Hodgkin lymphoma, with the small signal coming almost entirely from literature rather than human genetics (Open Targets Platform v4). The Claidex Mechanism Risk Score for MALT1 is in the yellow band, with the largest contribution from the genetic-evidence deficit (Open Targets association 0.0102).

Failure mechanism, best guess

A strategic stop at 9 patients is a portfolio decision layered on top of a hard scientific constraint. The constraint is the therapeutic window. MALT1 protease activity is required to maintain regulatory T cells, and sustained catalytic inhibition in mice drives a loss of Treg control and a multi-organ autoimmune and inflammatory phenotype (Journal of Neuroinflammation 2014, Cellular and Molecular Life Sciences 2016). A compound that must be dosed continuously to suppress tumor BCR signaling sits in direct tension with that liability, so the deliverable dose range can be narrow. When a crowded field already holds several inhibitors and degraders against the same node, a sponsor reading early tolerability and pharmacodynamic data through that lens can conclude the differentiated window is too small to justify continued spend. The termination is best read as translational risk converting into a capital-allocation call.

How to prevent this next time

Two quantitative tools would have sharpened the decision before nine patients were dosed. First, a Bayesian interim framework with an explicit posterior probability of success, updated on pharmacodynamic target-engagement and Treg-axis biomarkers rather than on response rate alone:

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

A prior anchored on the MALT1 class window and updated with the first cohorts of CYLD-cleavage and Treg readouts would have produced a numeric stop or go, not a narrative one. Second, a biomarker-enrichment and therapeutic-index calculation that pairs the dose needed for tumor pathway suppression against the dose that begins to erode Treg markers, expressed as a margin with confidence intervals. A target index below a prespecified threshold would flag the program for redesign toward intermittent dosing or combination at lower exposure. A competitive landscape red-team, scoring the differentiated window against the active inhibitor and degrader programs, would have made the portfolio question explicit at protocol design rather than after enrollment. The single highest leverage change would have been a predefined pharmacodynamic therapeutic-index gate, with a Bayesian posterior threshold, that the first three cohorts had to clear before further escalation.

What this means for similar programs

MALT1 remains a mechanistically attractive node, but the programmatic saturation around it means new entrants need a window argument, not just a potency argument. Programs should treat the Treg liability as a primary design variable, instrument it from the first cohort, and pre-commit to intermittent or combination strategies that protect the index. Targets with strong pathway logic and weak human genetic support, which describes MALT1 in non-Hodgkin lymphoma at an Open Targets score of 0.0102, carry elevated translational risk that should be priced into go and no-go thresholds before first patient in.

Open questions

Did the first cohorts show target engagement at tolerated doses, and was the strategic stop informed by an unfavorable pharmacodynamic margin that was never disclosed. Would intermittent dosing have widened the Treg-versus-tumor window enough to matter. Does the BCL10-MALT1 interaction strategy escape the protease-linked autoimmune liability, or inherit it. How much of the decision reflected the crowded competitive field rather than ONO-7018 itself.

Sources

1. • ClinicalTrials.gov, NCT05515406, study record, enrollment 9 (actual), reason for termination, primary completion 13 August 2025. - Open Targets Platform v4, MALT1 (ENSG00000172175) association with non-Hodgkin lymphoma (EFO_0005952), score 0.0102. - Nature Immunology 2008, MALT1 paracaspase cleavage in TCR signaling,- Clinical Cancer Research 2013, targeting MALT1 paracaspase activity in lymphoma,- Cancer Treatment Reviews 2023, function and targeting of MALT1 in cancer,- Journal of Clinical Investigation 2025, BCL10-MALT1 interaction inhibitor,- Cellular and Molecular Life Sciences 2016, MALT1 biological function and therapeutic potential,- Journal of Neuroinflammation 2014, MALT1 protease inhibition and autoimmune phenotype,- Claidex Mechanism Risk Score v1, MALT1 in the yellow band, computed from the live Supabase failure graph and Open Targets association score. Available from: https://clinicaltrials.gov/study/NCT05515406.